Michael Carter

Michael Carter

Director/Board Member presso ONCTERNAL THERAPEUTICS, INC.

Patrimonio netto: 34 429 $ in data 29/02/2024

86 anni
Health Technology
Finance
Commercial Services

Profilo

Michael G.
Carter
is on the board of Artios Pharma Ltd.
and Oncternal Therapeutics, Inc. In the past Dr. Carter was Non-Executive Chairman of Metris Therapeutics Ltd., Director-International Medical & Marketing at Zeneca Pharmaceuticals, Venture Partner at SV Health Investors LLP, Member-Pharmaceutical Board at AstraZeneca, Inc., Advisor at Healthcare Royalty Management LLC and Director-Pharmaceutical Division at Roche Products Ltd.
Michael G.
Carter
received a doctorate from The University of Sheffield and an undergraduate degree from UCL School of Pharmacy.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValorizzazioneData di valutazione
28/06/2023 3 702 ( 0.13% ) 34 429 $ 29/02/2024

Posizioni attive di Michael Carter

SocietàPosizioneInizio
ONCTERNAL THERAPEUTICS, INC. Director/Board Member 07/06/2019
Director/Board Member -
Tutte le posizioni attive di Michael Carter

Precedenti posizioni note di Michael Carter

SocietàPosizioneFine
Director/Board Member 22/08/2017
Director/Board Member 01/12/2014
Director/Board Member 01/01/2013
Director/Board Member 01/03/2012
Director/Board Member 25/02/2010
Vedi nel dettaglio l'esperienza di Michael Carter

Formazione di Michael Carter

The University of Sheffield Doctorate Degree
UCL School of Pharmacy Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Michael Carter

Relazioni

100 +

Relazioni di 1° grado

22

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private20

Health Technology

Finance

CancerVax Corp.

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Oncternal Therapeutics, Inc.

Vedi le connessioni aziendali
  1. Borsa
  2. Insiders
  3. Michael Carter